Photodynamic Inactivation Enhances Antibiotic Efficacy Without Affecting Drug Stability: Insights into Photosensitizer–Antibiotic Combination Therapies

Photodynamic inactivation (PDI) represents a promising strategy to overcome bacterial resistance by combining light, oxygen, and a photosensitizer (PS) to generate reactive oxygen species (ROS) that damage essential cellular components. Combining PDI with conventional antibiotics (ATBs) may further enhance bacterial eradication through complementary mechanisms. In this study, the tetracationic 5,10,15,20-tetra(4-<i>N</i>,<i>N</i>,<i>N</i>-trimethylammoniophenyl)porphyrin (TMAP⁴⁺) was evaluated in combination with ATBs: ampicillin (AMP) and rifampicin (RIF) against <i>Staphylococcus aureus</i> and cephalexin (CFX) against <i>Escherichia coli</i>. The photostability of all agents was assessed under the experimental irradiation conditions, and no evidence of physical interaction between TMAP⁴⁺ and the ATBs was detected. AMP and CFX remained photostable, while RIF exhibited only minimal photodegradation under white light, confirming its stability during PDI treatments. The antimicrobial assays revealed that irradiation significantly enhanced the bactericidal activity of TMAP⁴⁺. When combined with ATBs, photoactivated TMAP⁴⁺ led to a pronounced reduction in the minimum inhibitory concentration (MIC) values of AMP and RIF for <i>S. aureus</i> and of CFX for <i>E. coli</i>, indicating additive effects. Growth curve analyses corroborated these results, showing delayed bacterial growth and decreased maximal optical densities in the combined treatments compared to single agents. Overall, these findings demonstrate that the photodynamic process can potentiate the antimicrobial effect of conventional ATBs without compromising their stability, supporting the potential of PS-ATB combination therapies as a valuable approach to improve antibacterial efficacy and mitigate ATB resistance.